Current Edition

Volume 15 Issue 2

Gene Edited iPSCs May Find a Place in Allogeneic Therapies

An Introduction to Pluripotency Pluripotent: adjective; capable of giving rise to many different cell types. This is the hallmark characteristic of the induced pl...
Continue Reading →

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-...
Continue Reading →